Eventus Diagnostics

Company Overview

Snapshot

Founded in June 2010 by Alon Hayka and Marvin Rosenberg, Eventus Diagnostics operates with 11–50 employees. The company has raised $2.72 million across one funding round. In April 2014, EventusDx completed a $2.72 million financing round to support the development and commercialization of its Octava breast cancer tests.

Business overview

Eventus Diagnostics is a life sciences company focused on developing accurate and cost-effective blood tests that measure cancer-specific autoantibodies. The company's core products, the Octava Pink and Octava Blue tests, provide diagnostic information to improve breast cancer diagnosis by assessing mammography screening results. These tests aim to confirm true negative findings, identify false negatives, and reduce unnecessary biopsies caused by false positives, serving the healthcare and life sciences sectors, particularly laboratories and providers.

Strategic signal

In June 2014, Eventus Diagnostics was highlighted for its breakthrough in developing the first blood test for breast cancer. This development signals a significant advancement in diagnostic capabilities within oncology, offering a less invasive and potentially more accurate method for early detection and diagnosis. For investors, this indicates the company's potential to disrupt traditional breast cancer screening methods and improve patient outcomes.

Company Intelligence Q&A

What is Eventus Diagnostics' primary focus?

Eventus Diagnostics is an emerging life sciences company developing accurate and cost-effective blood tests that measure cancer-specific autoantibodies for improved breast cancer diagnosis.

When was Eventus Diagnostics founded and by whom?

Eventus Diagnostics was founded in June 2010 by Alon Hayka and Marvin Rosenberg.

What are the key products offered by Eventus Diagnostics?

The company's key products are the Octava Pink and Octava Blue tests, designed to provide additional diagnostic information for breast cancer screening, confirming mammography findings and reducing unnecessary biopsies.

What was a significant financial milestone for Eventus Diagnostics?

In April 2014, EventusDx completed a $2.72 million financing round to support the development and commercialization of its Octava breast cancer tests.

What impact do Eventus Diagnostics' products aim to have on breast cancer diagnosis?

The Octava Blue test aims to reduce the number of unneeded biopsies by at least 50%, saving women anxiety and invasiveness while reducing medical costs, by confirming abnormal mammography results and identifying false alarms.